A 36-Month Study on the Cost/Utility of Add-On Omalizumab in Persistent Difficult-to-Treat Atopic Asthma in Italy

201246 citationsJournal Article

Authors

Roberto W. Dal Negro · University of Verona

Abstract

The 36-month add-on omalizumab therapy persistently improved all clinical outcomes in difficult-to-treat asthmatic patients. Costs were also optimized and related to the extent of long-term health benefits achieved.

Topics & Keywords

Asthma and respiratory diseases Allergic Rhinitis and Sensitization Respiratory and Cough-Related Research

Publication Details

Published in: Journal of Asthma

Volume 49, Issue 8, pp. 843-848

DOI: 10.3109/02770903.2012.717659

Field-Weighted Citation Impact: 2.47

Command Palette

A 36-Month Study on the Cost/Utility of Add-On Omalizumab in Persistent Difficult-to-Treat Atopic Asthma in Italy

Authors

Abstract

Topics & Keywords

Publication Details